Oslo, Norway, 3 August 2021

Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for
PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin[® ]([177]Lu lilotomab
satetraxetan) in 3[rd]-line relapsed rituximab/anti-CD20 refractory follicular
lymphoma (3L R/R FL). The Company, having reviewed the recent rate of patient
recruitment in discussion with its clinical advisors and in light of the
continuing impact from the COVID pandemic, now anticipates the preliminary three
-month data readout from PARADIGME during the first half of 2022.

The Company will host a live webcast and Q&A on Thursday, 5 August 2021, at
08.30 CEST. A link to the webcast will be available in the afternoon on
Wednesday, 4 August on www.nordicnanovector.com.

The Company reports that 92 patients have been enrolled into PARADIGME as of 3
August, compared with 83 patients enrolled as of 25 May 2021 and 73 as of 17
February 2021.

While the changes to the PARADIGME protocol and initiatives implemented to
improve execution of the trial have positively impacted recruitment, the ongoing
COVID pandemic situation, exacerbated by the spread of the more infectious SARS
-CoV-2 delta variant, continues to affect the Company's ability to screen, enrol
and treat new patients. This is because the physical condition of the patient
population targeted for this study means they are at the greatest risk from
COVID-19 infection. As a result, the rate of patient recruitment has been slower
than anticipated.

Nordic Nanovector continues to prioritise and commit all necessary resources to
the completion of PARADIGME. As part of this prioritisation, Nordic Nanovector
has decided to close clinical sites at which enrolment has been particularly
challenging and refocus resources on other initiatives